logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HER2+ metastatic breast cancer: patients prefer subcutaneous over IV trastuzumab

ChangHER study participants were overwhelming in favor of SC over IV drug.